{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002591","form_type":"8-K","ticker":"ENZN","cik":"0000727510","company_name":"Viskase Holdings, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.209355+00:00","generated_at":"2026-05-28T05:56:07.971480+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enzon appoints Stephen T. Wills to board; forms special committee to evaluate Viskase proposal","bullets":["Board increased to four; Stephen T. Wills appointed as director effective January 7, 2025.","Special committee of independent directors (Randolph Read chair, Wills member) formed to evaluate any transaction proposed by Viskase Companies.","No terms of the proposal have been received; no decision made and no assurance any transaction will result.","Wills is CFO/COO of Palatin Technologies, CPA, with board experience at MediWound and other biopharma firms."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002591","json":"https://secwatch.observer/filing/0001104659-25-002591.json","markdown":"https://secwatch.observer/filing/0001104659-25-002591.md","text":"https://secwatch.observer/filing/0001104659-25-002591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/727510/000110465925002591/0001104659-25-002591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/727510/000110465925002591/tm252980d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:56:07.971480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f9f8f19e8","claim":"Stephen T. Wills was appointed as Director at Viskase Holdings, Inc..","evidence_excerpt":"On January 7, 2025, the Board of Directors (the “Board”) of Enzon Pharmaceuticals, Inc. (the “Company”) approved an increase in the number of directors on the Board to four and appointed Stephen T. Wills as a director, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/727510/000110465925002591/0001104659-25-002591-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}